Novavax, Inc.
NVAX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1 | $0 |
| % Growth | -70.6% | -64.1% | 654.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $1 | $0 |
| % Margin | 69.5% | 94.1% | 97.9% | 58.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | $0 | $1 | -$0 |
| % Margin | -252.7% | 44.2% | 77.3% | -148.4% |
| Other Income/Exp. Net | -$0 | $0 | $0 | $0 |
| Pre-Tax Income | -$0 | $0 | $1 | -$0 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$0 | $0 | $1 | -$0 |
| % Margin | -287.3% | 44.5% | 77.8% | -91.8% |
| EPS | -1.25 | 0.66 | 3.22 | -0.51 |
| % Growth | -289.4% | -79.5% | 731.4% | – |
| EPS Diluted | -1.25 | 0.6 | 2.93 | -0.51 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | $0 | $1 | -$0 |
| % Margin | -271.1% | 50.4% | 80.1% | -60.6% |